Kornimate/medical-research-clean huggingface dataset:
telerehabilitation approaches in chronic obstructive pulmonary patients

Conditions: Telerehabilitation; COPD

Summary: pulmonary rehabilitation (pr) is a first-line management strategy in chronic obstructive pulmonary patients (copd) as it reduces shortness of breath, increases exercise capacity, and improves health-related quality of life. however, 8-50% of patients referred to pr do not participate at all, while 10-32% of those who start do not complete the program. barriers to participation and completion include difficulty in accessing the program, poor mobility, lack of transport, and travel costs. telerehabilitation is defined as the provision of rehabilitation services through telecommunication technology, including telephone, internet and video conference communications between the patient and the healthcare provider. different technologies (from phone to video conferencing) have been tested in patients with copd to enhance daily activities, exercise training and walking prescription. all of them showed positive effects on exercise tolerance, dyspnea, physical activity and quality of life. however, there is no study about which telerehabilitation program is more effective on copd patients. the aim of this study is to investigate which telerehabilitation approach is more effective in copd.


Eligibility criteria:
inclusion criteria: * being diagnosed with copd (fev1 / fvc \<70% in the stable phase of the disease) * age \> 18 years old * have the ability to use a smartphone exclusion criteria: * musculoskeletal disorders that limit exercise * dizziness, significant sensory or motor impairments, dementia or terminal illnesses that prevent education * serious comorbidities such as unstable heart disease, irregular diabetes, known malignant disease, any other disease that makes the patient unsuitable for participation in the study. * incompatible patient * severe vision or hearing impairment * unwillingness or inability to follow the protocol * have had a copd exacerbation in the previous 6 weeks
korean post-marketing surveillance vyndamax® capsules for the treatment of transthyretin amyloid cardiomyopathy

Conditions: ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Summary: this non-interventioal study will be performed by design of post-marketing surveillance (pms) as an additional pharmacovigilance activity of the risk management plan (rmp) for vyndamax® capsules, which is required by the ministry of food and drug safety (mfds) according to the local regulation. this post-marketing surveillance will investigate the safety and effectiveness of vyndamax® capsules as the treatment of transthyretin amyloid cardiomyopathy during 10 years under the setting of routine practice in korea.


Eligibility criteria:
\*inclusion criteria: patients must meet all of the following inclusion criteria to be eligible for inclusion in the study: * 1. adult patients with the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm) * 2. patients to whom vyndamax® capsules is prescribed for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm) * 3. evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. * exclusion criteria patients meeting any of the following criteria will not be included in the study according to the local product label: * 1. patient with hypersensitivity or case history to tafamidis or to any of the excipients in the product * 2. this product contains sorbitol (e420). patients with rare hereditary problems of fructose intolerance should not take this medicine. * 3. patient who has a contraindication to vyndamax® capsules according to the approved local product label
aft: introduction of a full breast reconstructive method

Conditions: Breast Cancer; Reconstructive Surgery; Breast Reconstruction

Summary: a multicentre prospective cohort study will monitor the efficacy and safety of autologous fat transfer (aft) with pre-expansion. aft will be evaluated in terms of quality of life, aesthetic result, complications, oncological safety and cost-effectiveness. it follows the breast trial, the randomised controlled trial comparing aft with implant-based reconstruction. in this study, patients all receive aft.


Eligibility criteria:
inclusion criteria: * female gender * age of 18 years and older * history or in candidate for a mastectomy procedure in the near future * patients undergoing preventive mastectomy * patients' choice to undergo a breast reconstruction * wanting to participate in this study * patient is able to wear the external expansion device exclusion criteria: * active smoker or a history of smoking 4 weeks prior to surgery * current substance abuse * history of lidocaine allergy * history of silicone allergy * 4 weeks or less after chemotherapy * history of radiation therapy in the breast region * oncological treatment includes radiotherapy after mastectomy * kidney disease * steroid dependent asthma (daily or weekly) or other diseases * immune-suppressed or compromised disease * uncontrolled diabetes * bmi\>30 * large breast size (i.e. larger than cup c), unless the patient prefers reduction of the contralateral side towards cup c * extra-capsular silicone leaking from the encapsulated implant from a previous breast reconstruction * the treating plastic surgeon has strong doubts on the patient's treatment compliance
development of outcome-measures for physically active patients with hip and groin pain

Conditions: Hip Disability; Groin Disability

Summary: the aim of this study is to develop an evaluative questionnaire, to evaluate patients with hip and groin disability, and a strength measurement for the hip, for patients with hip and groin disability. both measurement instrument are aimed for evaluating the natural course and different treatment modalities in patients with hip and groin disability.


Eligibility criteria:
inclusion criteria: * hip and/groin pain more than 6 weeks * physically active exclusion criteria: * systemic diseases * physically inactive

Keywords: questionnaire hip groin disability strength to develop two new outcome measures for patients with hip and groin disability
synbiotic formula (scv09) in alzheimer's disease patients

Conditions: Alzheimer Disease

Summary: in recent years, emerging studies have revealed the role of gut microbiota in human health and diseases, including ad and other neurodegenerative conditions5. although the underlying mechanism is still largely unknown, successful therapies targeting the gut-brain axis may serve as indirect evidence of the possible linkage. this pilot, single-arm study aims to estimate the efficacy and assess the safety profile of the use of a new synbiotic formula (scv09) in improving dementia-related behaviour in alzheimer's disease patients, paving the way for a large-scale randomised controlled trial in the future.


Eligibility criteria:
inclusion criteria: * individuals aged between 60-85 with a clinical diagnosis of alzheimer's disease * hong kong version of montreal cognitive assessment (hk-moca) score of ≤20 * neuropsychiatric inventory-questionnaire (npi-12) ≥10 * stable medication history for alzheimer's disease within the past 4 weeks * have been taken care by a responsible caregiver who could assist the patient in taking the study products, collecting stool samples and attending the clinical follow-up •-able to provide informed consent exclusion criteria: * concomitant parkinson's disease and other neurodegenerative conditions affecting activities of daily living * history of stroke * history of severe organ failure (including decompensated cirrhosis), renal failure on dialysis, suffering from human immunodeficiency virus infection * confirmed active malignancy * known operations involving small intestines and large intestines; or history of appendectomy, hysterectomy, and cholecystectomy in last 6 months * use of anti-psychotics, antidepressants or sedatives, unless on a stable dose in the last 3 months * inability to receive oral fluids * use of antibiotics, probiotics or prebiotics in the last 2 weeks * intolerance to probiotics or lactose
the burden of covid-19 survivorship

Conditions: Covid19

Summary: this research study is being done to find out what the longer-term physiological consequences of covid-19 are, and to determine if exercise therapy can help improve lung function, heart function and overall fitness, and reduce symptoms in people recovering from sars-cov-2.

the purpose of this research is to see if taking part in structured exercise training will improve the ability to exercise, the function of the lungs and the function of the heart, and reduce symptoms of fatigue and breathlessness in people recovering from covid-19. after enrollment all patients will complete exercise testing, lung function testing, and cardiac imaging. patients will be randomized to either 8 weeks of exercise training (4-5 times per week) or will continue standard medical care. all patients will undergo detailed exercise testing, lung function testing, and cardiac imaging after the intervention.

Eligibility criteria:
inclusion criteria: * aged 21 to 75 years. * history of rt-pcr proven sars-cov-2 infection. * deemed 'recovered' from sars-cov-2 infection. * not clinically obese (bmi ≥ 36) and/or suffer from musculoskeletal or other conditions that would limit exercise participation. * no evidence of cardiac ischemia at rest or during exertion (via ecg). * able to provide written informed consent. exclusion criteria: * individuals less than 21 or more than 75 years old. * not able to take part in structured exercise training due to injury or other conditions that would put person at risk during exercise. * unable to provide written informed consent.
myocardial fibrosis and inflammation in liver cirrhosis

Conditions: Cirrhosis, Liver; Cardiomyopathies; Portal Hypertension

Summary: the aim of this clinical prospective study is to assess structural and functional myocardial changes in patients with liver cirrhosis after implantation of transjugular intrahepatic portosystemic shunt (tips).


Eligibility criteria:
inclusion criteria: * liver cirrhosis with evaluation of tips implantation * patients who are 18 years of age or older exclusion criteria: * underlying cardiac disease, e.g. known myocardial infarction, previous myocarditis, congenital heart disease, cardiomyopathies of other causes known underlying disease witt potential cardiac involvement, e.g. storage disease (e.g. hemochromatosis, fabry disease), inflammatory (e.g. sarcoidosis), endocrinological (e.g. diabetes mellitus, hyper-/hypothyroidism), autoimmune (e.g. systemic lupus erythematosus, dermatomyositis, rheumatoid arthritis), therapeutic (chemotherapy). * patients with contraindication for contrast-enhanced mri * pregnant and breastfeeding women
impact of muscle afferent feedback during exercise in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: recently, direct evidences point to the contributing role of peripheral muscle fatigue in exercise tolerance among patients with copd. however, the physiological mechanisms by which peripheral muscle fatigue impairs exercise tolerance are still unknown, as factors regulating peripheral muscle fatigue in copd may be complex. one possible link between limb muscle fatigue and exercise intolerance could be enhanced afferent signals from the active limb muscles to the central command, thereby limiting central motor output and eventually leading to exercise termination. a direct method to investigate the regulation of peripheral muscle fatigue during exercise in patients with copd is the blockade of peripheral neural afferents via lumbar anesthesia. consequently, investigating the interplay between the peripheral muscular component and the central motor command during self-paced exercise could shed light on the regulation of peripheral muscle fatigue in copd and its implication in exercise intolerance.

the aim of the study is to characterize the role of peripheral muscle afferents on the development of muscle fatigue, cardiorespiratory response and exercise tolerance to constant-workrate endurance cycling exercise in patients with copd. in a double-blind randomized design, patients with gold stage ii-iii copd will be recruited and will complete a constant-workrate cycling test following either the injection of a placebo \[nacl, interspinous l2-l3\] or an opioid \[fentanyl 25 µg, intrathecal l2-l3\] inhibiting central feedback of peripheral muscles sensory afferents. quadriceps force (twq) will be measured by magnetic stimulation of the femoral nerve and central chemoreceptors response will be assessed by co2 rebreathing, both performed before and after the injection. finally, twq will also be measured after the endurance cycling test to assess the magnitude of quadriceps fatigue induced by symptom-limited exercise.

Eligibility criteria:
inclusion criteria: * smoking history \> 15 pack-years * copd gold ii-iii (30 % predicted \< fev1 \< 80 % predicted; fev1/fvc \< 0.70) exclusion criteria: * unstable condition * recent exacerbation (\<3 months) * recent cancer (\<3 months) * myopathy, neuromuscular disease * unstable cardiac disease * hepatic, kidney, intestinal disease * bmi \> 35 * paco2 \> 45 mmhg * pao2 \< 60 mmhg

Keywords: chronic pulmonary obstructive disease muscle dysfunction exercise intolerance muscle afferents ventilation
the use of ct perfusion to determine the normalization window period in the treatment of advanced primary lung adenocarcinoma with endostar

Conditions: Advanced Primary Lung Adenocarcinoma

Summary: to evaluate the change of blood perfusion before/after the use of endostar, discuss the time sequence of endostar tm in treating advanced lung adenocarcinoma in normalization window period.


Eligibility criteria:
inclusion criteria: * histologically or cytologically newly diagnosed as unresectable and metastasis advanced lung adenocarcinoma(stage iv, seventh edition of the uicc/ajcc classification for lung cancer). * at least one measurable objective tumor lesion, spiral ct or pet-ct examination: the shortest diameter ≥2cm，and no obvious necrosis * life expectancy ≥12weeks * patients receive palliative radiotherapy for bone's pain relief; patients receive radiotherapy for brain metastasis、patients after brain transfer operation or radiation therapy are allowed to enter the research. * 18≤patients'age \<70 years. * electrocolonogram (ecog) score:0-1. * granulocyte count ≥ 2.0×109/l, platelet count ≥ 100×109/l. * serum bilirubin within the normal range. * aspartate aminotransferase ( ast ), alanine aminotransferase ( alt ) within the normal range(if the patients is diagonosed as liver metastasis,his/her ast/alt should not surpass 1.5 times of the normal range ). * serum creatinine within the normal range and creatinine clearance rate ≥60ml/min * compliance with research requirements and be able to follow up. * within 72 hours before the treatment, all women pregnant with pregnant possibility should undergo pregnancy test and get negative results. * patients with fertility ability should take effective contraceptive techniques. * sign informed consent of this clinic trial. exclusion criteria: * lung adenocarcinoma patients who received systemic chemotherapy/thoracic radiotherapy/targeted therapy * received resection, cutting or aspiration within seven days * any unstable systemic diseases (including peptic ulcer、active infection、grade4 hypertension、unstable angina、congestive heart failure、liver, metabolic disorders or fracture、unhealing wound ) * chronic kidney disease history(including chronic nephritis, nephrotic syndrome, obstruction of urinary tract etc. caused by urinary calculus) * have to use anticoagulant drugs at the same time * patients with obvious coagulation disorders、active bleeding and bleeding tendency * any other malignancies (complete cure of cervical carcinoma in situ/basal cell carcinoma/squamous cell carcinoma are excluded )happened within 5 years. * signifinant weight loss, weight lost during the 6 weeks more than or equal to 10% * patients who take bone metastasis as the only observing index * allergic to escherichia coli preparation * used endostar before * lactating women * contraindications written on pemetrexed、carboplatin、dexamethasone instructions * allergic to radiographic contrast agents * in the middle or planning to attend other clinic trails

Keywords: endostar ct perfusion advanced primary lung adenocarcinoma
perfusion abnormalities in hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy (HCM)

Summary: the purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.


Eligibility criteria:
inclusion criteria: * diagnosis of hypertrophic cardiomyopathy * subject being initiated on clinically-indicated cardiac myosin inhibitor therapy exclusion criteria: * pregnancy * lactation * allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson * serious ae to regadenoson * hypotension * serious bradycardia not addressed by pacemaker * moderate or greater reactive airways disease

Keywords: hypertrophic cardiomyopathy myocardial contrast echocardiography microvascular perfusion
an exploratory rct of a psychosocial group intervention for epilepsy

Conditions: Epilepsy

Summary: children and young people with epilepsy are at increased risk of poorer outcomes related to emotional and psychological adjustment, peer relationship problems, lower academic attainment and mental health problems across the lifespan. despite the well understood risks, there continues to be a lack of psychological and psychosocial support for young people with epilepsy, and a corresponding lack of evidence regarding the effectiveness of psychosocial interventions. this study aims to evaluate a manualised psychosocial group intervention for adolescents with epilepsy. a cognitive behaviour therapy approach is used, aimed at increasing awareness of how epilepsy may impact upon thoughts, feelings and activities and to develop strategies for improved psychological adjustment. in addition, an epilepsy knowledge component aimed at improving a sense of control and epilepsy self-management is included. a group delivery format allows an opportunity for social modelling, and social problem solving, helping others and relating to other young people with similar experiences. the social learning context and availability of knowledgable facilitators (an epilepsy nurse specialist and clinical psychologist) are also key aspects of the intervention. the study will allow us to establish a standard manualised group intervention that can be used throughout the uk which aims to; establish the effectiveness and desirability of this approach; improve the overall quality of life, psychological health and social integration of young people with epilepsy; and to improve epilepsy knowledge and selfmanagement skills aimed at maximising seizure control and overall management.


Eligibility criteria:
inclusion criteria: * written informed consent * diagnosis of epilepsy (controlled or refractory) of at least 6 months duration * between the ages of 1217 years old * have a reasonable level of expressive and receptive english language abilities to enable them to fully participate and contribute to the group process * in mainstream schooling. exclusion criteria: * formal diagnosis of learning disability or attendance at a school for children with special educational needs * complex and severe mental health problems; * diagnosis of nonepileptic seizures in the absence of epileptic seizures * epilepsies occurring in the context of: 1. postnatally acquired structural lesions (e.g. tbi or neurooncological conditions) 2. immune mediated disorders (e.g. limbic or antinmdar encephalopathy) 3. metabolic disorders (e.g. glut1 deficiency)

Keywords: epilepsy psychosocial
pulsed dye laser treatment of port wine stain birthmarks: comparison of 577 nm versus 595 nm wavelengths

Conditions: Port Wine Stains

Summary: port wine stain are a congenital, progressive vascular malformation of human skin. the pulsed dye laser is approved by the food and drug administration for the treatment of choice. however, the degree of port wine stain blanching seen following pulsed dye laser treatment remains variable and unpredictable. if the ultimate standard required is complete lesion blanching, the average success rate is below 10%, even after undergoing numerous pulsed dye laser treatments. moreover, less than 50% of patients achieve 50% fading of their port wine stain in response to pulsed dye laser therapy.

the researchers' specific aim is to determine whether the use of the pulsed dye laser operating at a wavelength of 577 nm will improve therapeutic outcome as compared to a pulsed dye laser operating at 595 nm. the researcher can treat port wine stain treated using a pulsed dye laser operating at a wavelength of 577 nm and the other half at a wavelength of 595 nm. the researcher can determine that the 577 nm pulsed dye laser improved port wine stain blanching responses more than the areas treated with 595 nm. the degree of port wine stain blanching which will determine by visible reflectance spectroscopy skin imaging device measurements. post-treatment blanching responses can compare with pre-treatment measurements of port wine stain fractional blood volume.

Eligibility criteria:
inclusion criteria: * port wine stain suitable for comparison testing * age \> 6 months of age; minor will be accompanied in the room by parents or guardians during laser treatment * apparent good health as documented by medical history * ability to understand and carry out subject instructions exclusion criteria: * history of photodermatoses or skin cancer * any therapy within the previous two months to the proposed port wine stain treatment sites * inability to understand and carry out instructions

Keywords: vascular malformation